Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston –– Women ...

Humacyte, Inc. (HUMA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access June 15, 2026 5:00 PM EDTCompany ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has ...

Humacyte recently reported research showing its acellular tissue engineered vessel (ATEV) used for dialysis access can self-repair after repeated needle cannulation, maintaining structural integrity ...

On June 10, 2026, Humacyte reported positive top-line interim results from its Phase 3 V012 trial evaluating its acellular tissue engineered vessel (ATEV) for dialysis access in female patients with ...

The size and price of the stock offering were not disclosed.

We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Humacyte, Inc. (NASDAQ:HUMA) is among the best penny stocks under $1 according to hedge funds. TheFly ...

Stock market movers today: futures rebound after AI sell-off as oil dips; see top gainers/losers like Navan, Oracle, Humacyte ...

The commercial-stage biotechnology platform company's acellular tissue engineered vessel had an average of 91 more catheter-free days compared to autologous arteriovenous fistula, the current standard ...

Oxford Industries reported a lower profit, citing the effects of tariff costs and macroeconomic pressures weighing on consumer sentiment. Shares fell 8.7%, to $39.50, after the bell. Humacyte reported ...